Free tool
Rare disease stocks
We cover 8 companies grouped under the Rare disease theme. The median market value in the group is $95.77M. Across the group, the median move over the past trading day is +0.41%. Price change over the past year runs from −91.3% to −9.0% across the middle 80 percent of the group, with a median of −67.4%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
8 of 268 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| VRTX34.SA | Vertex Pharmaceuticals Incorporated | $140.14B | Large cap | −83.17% |
| 0HD2.L | Alnylam Pharmaceuticals, Inc. | $35.05B | Large cap | −46.85% |
| SION | Sionna Therapeutics, Inc. | $282.58M | Small cap | −74.02% |
| 0RAG.L | ABIONYX Pharma SA | $95.77M | Micro cap | −18.26% |
| TENX | Tenax Therapeutics, Inc. | $86.82M | Micro cap | −60.81% |
| CVKD | Cadrenal Therapeutics, Inc. | $4.74M | Micro cap | −87.58% |
| ANR.AX | Anatara Lifesciences Ltd | $2.04M | Micro cap | +12.50% |
| 0JQ2.L | KALA BIO, Inc. | — | — | −99.82% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.